Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 08 September 2016 | By Zachary Brennan
As the open question around interchangeable biosimilars in the US continues to drive the discussion on what the US Food and Drug Administration (FDA) will require for such a designation, some experts are saying the designation might not actually be that important for the biosimilar market as a whole.
Ronny Gal, senior analyst in specialty pharmaceuticals equity research at Sanford Bernstein, told attendees at GPhA’s first biosimilars conference on Thursday that although interchangeability remains an open question, what’s really driving the development of biosimilars is the economics.
And even when the first interchangeable biosimilar is brought to market in the US (the EU does not have such a designation), Gal warns that there will be a lingering perception (no matter the lengths FDA and others go to to make clear that the interchangeable is no more effective or safe than other biosimilars for the same reference product) that the non-interchangeable biosimilar is somehow inferior to the interchangeable biosimilar.
“If you bring a biosimilar to market, and there’s an interchangeable on the market, it already looks like it’s an inferior product,” he said. “Be careful what you wish for.”
He also noted that the process of informing patients of a switch to either non-interchangeable biosimilars or interchangeable biosimilars will be the same (ie. Patients will see the new biosimilar product and have questions about the differences between the biosimilar and reference product and the switch between them).
Momenta Pharmaceuticals CEO Craig Wheeler said Thursday: “Interchangeability presents opportunities… There’s at least the perception of higher quality, so there is some advantage.”
But Wheeler also noted that the perception is “not as strong as when we first entered this business. These biosimilar programs will be accepted regardless of perception. There are instances where [interchangeables] will be strategically important but it’s not the be all, end all.”
Bert Liang, chair of the Biosimilars Council and CEO of Pfenex, added that interchangeability “has to be achievable,” in terms of the types of studies FDA requires, the return on investment and what patients can afford. If FDA requires four, or even 10 different studies, questions will arise on the return on investment, Liang said. “We have to push for reasonable expectations so if a manufacturer wants to go after it, it’s doable,” he said.
Another open question is what will happen if a biosimilar has already been placed on a formulary and then an interchangeable biosimilar for that same reference product is approved by FDA and comes to market. Will the interchangeable replace the biosimilar on the formulary? And will this perception of inferiority have an impact on whether a biosimilar or an interchangeable biosimilar is placed on a formulary? Or will the biosimilars industry evolve to a point where it's more similar to the generics industry where, as Gal said, "a generic is a generic is a generic"?
While answers to those questions might not be solved until the interchangeable biosimilar market becomes a reality, FDA's draft guidance on interchangeability, which many are saying has already been written and is just awaiting approval, is still on track for release in 2016, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, said Wednesday.
Tags: interchangeability, biosimilars, biologics and biosimilars, Momenta Pharmaceuticals, Pfenex, Sandoz, GPhA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.